TN2015000402A1 - Methods for treating crohn's disease using an anti-il23 antibody - Google Patents

Methods for treating crohn's disease using an anti-il23 antibody

Info

Publication number
TN2015000402A1
TN2015000402A1 TN2015000402A TN2015000402A TN2015000402A1 TN 2015000402 A1 TN2015000402 A1 TN 2015000402A1 TN 2015000402 A TN2015000402 A TN 2015000402A TN 2015000402 A TN2015000402 A TN 2015000402A TN 2015000402 A1 TN2015000402 A1 TN 2015000402A1
Authority
TN
Tunisia
Prior art keywords
disease
antibody
methods
treating crohn
crohn
Prior art date
Application number
TN2015000402A
Other languages
English (en)
Inventor
Wayne Tsuji
Wei-Jian Pan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TN2015000402A1 publication Critical patent/TN2015000402A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
TN2015000402A 2013-03-15 2015-09-09 Methods for treating crohn's disease using an anti-il23 antibody TN2015000402A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789976P 2013-03-15 2013-03-15
PCT/US2014/018308 WO2014143540A1 (fr) 2013-03-15 2014-02-25 Méthodes de traitement de la maladie de crohn à l'aide d'un anticorps anti-il-23

Publications (1)

Publication Number Publication Date
TN2015000402A1 true TN2015000402A1 (fr) 2017-01-03

Family

ID=50236361

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2015000402A TN2015000402A1 (fr) 2013-03-15 2015-09-09 Methods for treating crohn's disease using an anti-il23 antibody

Country Status (17)

Country Link
US (5) US20160031983A1 (fr)
EP (2) EP2968486A1 (fr)
JP (4) JP2016516686A (fr)
KR (1) KR20150128859A (fr)
CN (1) CN105307675A (fr)
AP (1) AP2015008801A0 (fr)
AU (1) AU2014228553B2 (fr)
CA (1) CA2906384A1 (fr)
CL (1) CL2015002724A1 (fr)
EA (1) EA201591579A1 (fr)
HK (1) HK1220605A1 (fr)
IL (2) IL241343A0 (fr)
NZ (1) NZ712294A (fr)
PH (1) PH12015502133A1 (fr)
SG (2) SG11201507483PA (fr)
TN (1) TN2015000402A1 (fr)
WO (1) WO2014143540A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CA2816950C (fr) 2010-11-04 2018-11-27 Boehringer Ingelheim International Gmbh Anticorps anti-il-23
EA201401204A1 (ru) 2012-05-03 2015-05-29 Бёрингер Ингельхайм Интернациональ Гмбх Антитела к il-23p19
EP3708679A1 (fr) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarqueurs utiles dans le traitement de maladies liées à l'il-23a
PE20171139A1 (es) 2014-09-03 2017-08-09 Boehringer Ingelheim Int Compuesto dirigido a il-23a y tnf-alfa y sus usos
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
EP3978530A1 (fr) * 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Antagonistes d'intégrine bêta7 et procédés de traitement de la maladie de crohn
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
KR20180128471A (ko) * 2016-03-29 2018-12-03 얀센 바이오테크 인코포레이티드 항-il12 및/또는 항-il23 항체의 증가된 투여 간격을 사용한 건선의 치료
EP3848390A1 (fr) * 2016-10-14 2021-07-14 Boehringer Ingelheim International GmbH Procédés de traitement de maladies
US20210277105A1 (en) * 2018-07-13 2021-09-09 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
TW202103734A (zh) 2019-04-22 2021-02-01 美商美國禮來大藥廠 治療克隆氏症（ｃｒｏｈｎ＇ｓ ｄｉｓｅａｓｅ）的方法
CN114641493A (zh) * 2019-08-21 2022-06-17 阿斯特捷利康合作创业有限责任公司 使用布雷库单抗治疗克罗恩病
CN111956606B (zh) * 2020-08-31 2021-05-14 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
HUE042561T2 (hu) 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
US7872102B2 (en) 2005-08-25 2011-01-18 Eli Lilly And Company Anti-IL-23 antibodies
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
PL1931710T3 (pl) 2005-08-31 2017-06-30 Merck Sharp & Dohme Corp. Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej
US7686047B2 (en) * 2005-11-04 2010-03-30 Roger Cleveland Golf Co., Inc. Golf club cover
RS53685B1 (en) 2005-12-29 2015-04-30 Janssen Biotech Inc. HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
MX2009009079A (es) 2007-02-23 2009-08-31 Schering Corp Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) 2007-02-23 2009-11-02 Schering Corp Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US20090117289A1 (en) * 2007-10-09 2009-05-07 Enerize Corporation Method and apparatus for deposition of thin film materials for energy storage devices
WO2009082624A2 (fr) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonistes de il-17a, il-17f et il-23 et procédés d'utilisation de ceux-ci
RU2497545C2 (ru) * 2008-03-18 2013-11-10 Эбботт Лэборетриз Способ лечения псориаза (варианты)
CA2734919C (fr) 2008-08-27 2016-08-16 Schering Corporation Formulations lyophilisees d'anticorps anti-il-23p19 modifies
JP2012522749A (ja) 2009-04-01 2012-09-27 グラクソ グループ リミテッド 抗ｉｌ−２３免疫グロブリン
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
KR101766936B1 (ko) 2010-01-15 2017-08-09 키린-암젠, 인코포레이티드 항체 제제 및 치료 요법
WO2012009760A1 (fr) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anticorps spécifiques anti-hétérodimère il-23
SI2625199T1 (en) * 2010-10-08 2018-03-30 Novartis Ag Procedures for treating psoriasis using IL-17 antagonists
CA2816950C (fr) 2010-11-04 2018-11-27 Boehringer Ingelheim International Gmbh Anticorps anti-il-23
CN103596978A (zh) * 2011-01-07 2014-02-19 阿布维公司 抗il-12/il-23抗体及其用途

Also Published As

Publication number Publication date
JP2023012516A (ja) 2023-01-25
HK1220605A1 (zh) 2017-05-12
CL2015002724A1 (es) 2016-03-28
EP3693007A1 (fr) 2020-08-12
JP2016516686A (ja) 2016-06-09
EA201591579A1 (ru) 2016-01-29
AP2015008801A0 (en) 2015-10-31
AU2014228553B2 (en) 2019-01-24
KR20150128859A (ko) 2015-11-18
EP2968486A1 (fr) 2016-01-20
IL275092A (en) 2020-07-30
US20200283517A1 (en) 2020-09-10
CA2906384A1 (fr) 2014-09-18
US20180327490A1 (en) 2018-11-15
US20200017581A1 (en) 2020-01-16
JP2021107397A (ja) 2021-07-29
NZ712294A (en) 2020-04-24
CN105307675A (zh) 2016-02-03
US20170218062A1 (en) 2017-08-03
AU2014228553A1 (en) 2015-10-08
US20160031983A1 (en) 2016-02-04
IL241343A0 (en) 2015-11-30
JP2020073470A (ja) 2020-05-14
SG11201507483PA (en) 2015-10-29
PH12015502133A1 (en) 2016-01-25
SG10201805015TA (en) 2018-07-30
WO2014143540A1 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
TN2015000402A1 (fr) Methods for treating crohn's disease using an anti-il23 antibody
PH12019502700A1 (en) Methods for treating psoriasis using an anti-il-23 antibody
BR112018003984A2 (pt) anticorpos
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
BR112018073574A2 (pt) conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112017002183A2 (pt) conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
PH12017501659A1 (en) Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2015016627A (es) Vacuna para la malaria.
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
MX2019008779A (es) Antigenos de pseudomonas y combinaciones de antigenos.
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2019004802A (es) Determinacion de dosis para los agentes inmunoterapeuticos.